Imovane

Zopiclone, the active ingredient in Imovane, is a cyclopyrrolone presented as a tablet for oral use. It is prescribed to adults who experience difficulty falling asleep or staying asleep, helping to improve sleep onset and maintenance. The drug acts on the central nervous system to promote sedation and is classified under the therapeutic class of sedative/hypnotics.

GNH USA supplies Imovane as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved products to meet the needs of healthcare providers across multiple regions.

Zopiclone is a cyclopyrrolone used to treat sleep disorders, primarily insomnia, by enhancing GABA‑mediated inhibition to promote sedation. - Insomnia: helps adults achieve faster sleep onset and improve overall sleep duration. - Sleep‑onset insomnia: reduces the time required to fall asleep. - Sleep‑maintenance insomnia: decreases nighttime awakenings and promotes continuous sleep. - Short‑term insomnia: provides temporary relief for acute sleep disturbances lasting up to four weeks. - Insomnia related to shift work: assists individuals with irregular sleep schedules to obtain restorative sleep.

Zopiclone may cause a range of adverse reactions, which are classified by frequency.

Common Side Effects: - Drowsiness: feeling of sleepiness during daytime. - Bitter taste: unpleasant metallic taste in the mouth. - Dry mouth: reduced salivary secretion. - Headache: mild to moderate head pain. - Dizziness: sensation of light‑headedness or unsteadiness. - Nausea: mild stomach upset or queasiness.

Serious or Rare Side Effects: - Complex sleep behaviours: sleepwalking, sleep‑driving, or performing other activities while not fully awake. - Allergic reactions: rash, itching, swelling, or difficulty breathing. - Dependence or withdrawal: signs of physical or psychological dependence with abrupt cessation. - Mood changes: depression, anxiety, or suicidal thoughts in rare cases.

When prescribing Zopiclone, clinicians should consider several precautionary measures to ensure safe use. - Assess patient history: evaluate for prior substance abuse, depression, or respiratory disorders. - Limit duration: use the lowest effective dose for the shortest period, typically ≤4 weeks. - Avoid alcohol: concurrent intake can enhance sedative effects and respiratory depression. - Caution in the elderly: increased sensitivity may raise risk of falls and cognitive impairment. - Pregnancy and lactation: weigh benefits against potential risks; use only if clearly needed. - Store at ambient temperature: keep tablets in the original container, protect from moisture and light.

Zopiclone can interact with other medicines, altering its sedative effect or safety profile.

Major Interactions (Avoid): - Central nervous system depressants: concurrent use with opioids, barbiturates, or antihistamines may cause profound sedation or respiratory depression. - CYP3A4 inhibitors: strong inhibitors such as ketoconazole or itraconazole can increase Zopiclone plasma levels, raising toxicity risk. - Alcohol: combined use markedly enhances sedation and impairs psychomotor performance.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers: agents like rifampicin may reduce Zopiclone effectiveness. - Other hypnotics: co‑administration with benzodiazepines may increase cumulative sedative burden. - Antidepressants: certain SSRIs can modestly affect Zopiclone metabolism, requiring observation.